{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:20Z","timestamp":1789609220089,"version":"build-2803163510"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pure red cell aplasia (PRCA) is a well\u2010documented potential side effect of ABO major mismatched allogeneic hematopoietic stem cell transplants. This side effect may be self\u2010limiting, but is sometimes treated using modalities such as steroids, antithymocyte globulin, donor lymphocyte infusions, rituximab, or plasma exchanges. Another well\u2010documented cause of pure red cell aplasia is a chronic parvovirus B19 infection, which may be seen in immunocompromised hosts. The treatment of this cause of PRCA includes removal of immunosuppression, intravenous immunoglobulin (IVIg), or rituximab; however, this condition may also be self\u2010limiting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Report<\/jats:title><jats:p>We show a case of a patient with PRCA who had previously received an ABO major mismatched allogeneic hematopoietic stem cell transplant, but also had an identified source of parvovirus B19 in his marrow post\u2010transplant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>He underwent several various treatments for his PRCA, including rituximab, bortezomib, and then plasma exchange. Anti\u2010A IgM and IgG titers were drawn throughout his treatment course, and fell from 512 (anti\u2010A IgM) and 1024 (anti\u2010A IgG) to 2 (anti\u2010A IgM) and 8 (anti\u2010A IgG). After his last plasma exchange procedure, the patient's hemoglobin and reticulocyte count rose from 6.6 g\/dL and 12.5 \u00d7 10<jats:sup>9<\/jats:sup>\/L (respectively) at the onset of the PRCA diagnosis to 9.6 g\/dL and 138.1 \u00d7 10<jats:sup>9<\/jats:sup>\/L after a series of 14 plasma exchanges.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This demonstrates a case of PRCA caused by an ABO major mismatched allogeneic hematopoietic stem cell transplant that was potentially complicated by a parvovirus infection, which was treated with multiple therapeutic interventions including a series of therapeutic plasma exchanges, rituximab, and bortezomib. Successful resolution of the patient's PRCA was achieved.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jca.21553","type":"journal-article","created":{"date-parts":[[2017,5,25]],"date-time":"2017-05-25T16:45:42Z","timestamp":1495730742000},"page":"108-112","source":"Crossref","is-referenced-by-count":27,"title":["Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-9386","authenticated-orcid":false,"given":"Katie","family":"Sackett","sequence":"first","affiliation":[{"name":"Departments of Laboratory Medicine and Pathology and Pediatrics Blood and Marrow Transplantation University of Minnesota Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia S.","family":"Cohn","sequence":"additional","affiliation":[{"name":"Departments of Laboratory Medicine and Pathology and Pediatrics Blood and Marrow Transplantation University of Minnesota Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Fahey\u2010Ahrndt","sequence":"additional","affiliation":[{"name":"Departments of Laboratory Medicine and Pathology and Pediatrics Blood and Marrow Transplantation University of Minnesota Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Departments of Laboratory Medicine and Pathology and Pediatrics Blood and Marrow Transplantation University of Minnesota Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Departments of Laboratory Medicine and Pathology and Pediatrics Blood and Marrow Transplantation University of Minnesota Minneapolis Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,24]]},"reference":[{"issue":"1","key":"e_1_2_5_2_1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V75.1.290.290","article-title":"Pure red\u2010cell aplasia of long duration complicating major ABO\u2010incompatible bone\u2010marrow transplantation","volume":"75","author":"Gmur JP","year":"1990","journal-title":"Blood."},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40050543.x"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.03.018"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03295.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704264"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1607-551X(09)70096-8"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0304-8"},{"issue":"3","key":"e_1_2_5_9_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1083-8791(98)50004-3","article-title":"Prolonged erythroid aplasia after major ABO\u2010mismatched transplantation for chronic myelogenous leukemia","volume":"4","author":"Benjamin RJ","year":"1998","journal-title":"Biol Blood Marrow Transplant."},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.36.487"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13269"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703668"},{"issue":"3","key":"e_1_2_5_13_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5114\/wo.2012.29287","article-title":"Rituximab is highly effective for pure red cell aplasia and post\u2010transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation","volume":"16","author":"Kopinska A","year":"2012","journal-title":"Wspolczesna Onkol."},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.04.004"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12210"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-25-2-151"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/152.2.257"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1046"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07216.x"},{"issue":"4","key":"e_1_2_5_20_1","first-page":"195","article-title":"[Parvovirus B19 infection]","volume":"12","author":"Araujo F","year":"1999","journal-title":"Acta Med Port."},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.5458"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1990.tb02086.x"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37997454023.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03741.x"},{"key":"e_1_2_5_25_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tme.12121","article-title":"Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO\u2010incompatible haematopoetic stem cell transplantation","author":"Khan F","year":"2014","journal-title":"Transfus. Med."},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(97)90146-5"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.140151"},{"key":"e_1_2_5_28_1","unstructured":"AABB Technical Manual 18th Edition."},{"key":"e_1_2_5_29_1","doi-asserted-by":"crossref","unstructured":"Daniels Essential Guide to Blood Groups.2010.","DOI":"10.1002\/9781444325188"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.21553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.21553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:51:37Z","timestamp":1695549097000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.21553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,24]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/jca.21553"],"URL":"https:\/\/doi.org\/10.1002\/jca.21553","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,24]]}}}